Retina Implant's first clinical trial results presented at 2010 AAO annual meeting

Retina Implant AG, a leading developer of subretinal implants for the visually impaired, is proud to announce Co-Founder and Chairman Eberhart Zrenner, M.D. was invited to present the exciting results of clinical trials he has been leading since 2005 by the American Academy of Ophthalmology at this year's annual meeting that took place October 16-19 at McCormick Place in Chicago, Ill.

“As we continue on with our second clinical trial, we look forward to expanding on the lessons learned during our first trial by following patients as they return home.”

Due to personal reasons, Dr. Zrenner was unable to attend. Dr. Walter-G. Wrobel, CEO of Retina Implant AG, delivered the presentation titled, "Subretinal Implants for Retinitis Pigmentosa" as part of AAO's Retina Subspecialty Day on Saturday, October 16. The presentation discussed findings from Retina Implant's first clinical trial which began in November 2005 and involved implanting 11 patients with a 1500 electrode microchip subretinally. Dr. Wrobel explained how the trial was carried out, the subretinal technique to implantation, and the visual results achieved by patients including the ability to recognize foreign objects and read at a basic level.

"The stellar results achieved during our first clinical trial validate our subretinal approach to implantation which we believe is the key to restoring useful vision for patients blind by retinitis pigmentosa," said Walter-G. Wrobel, CEO of Retina Implant AG. "As we continue on with our second clinical trial, we look forward to expanding on the lessons learned during our first trial by following patients as they return home."

Retina Implant began their second clinical trial earlier this year in Germany with plans to expand the trial to other European countries including the U.K. and Italy. In this clinical trial patients will receive the 1500 electrode implant permanently. Pending positive results from their second clinical trial, Retina Implant intends to submit for CE mark approval.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Weight loss drug semaglutide may offer relief for knee arthritis pain